Skip to main content

DiaGenic Taps Ferrer InCode as Distributor

NEW YORK (GenomeWeb News) – Norwegian gene expression-based diagnostics company DiaGenic said today that it has signed up Ferrer InCode to distribute its Alzheimer's disease test in certain countries in Europe and Latin America.

Barcelona, Spain-based Ferrer InCode will distribute the ADtect test for early diagnosis of Alzheimer's disease in Germany, Belgium, France, the Netherlands, Italy, Spain, and Portugal, as well as in Latin American nations.

A subsidiary of Grupo Ferrer International, Ferrer InCode is focused on offering personalized medicine products including prognostic and predictive technologies based on genomics, proteomics, metabolomics, and bioinformatics.

"Early detection enables subsequent early initiation of active management strategies, which may preserve the patients' level of function for longer and increases the chances of delaying the progression of the disease," DiaGenic CEO Erik Christensen said in a statement.

"Current evidence suggests that pharmacological treatments and caregiver interventions can delay entry into nursing homes, thus reducing healthcare costs," Christensen added. "However, these cost savings are not being realized because many patients with Alzheimer's disease are either not diagnosed or diagnosed at a late stage of the disease."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.